Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities

摘要: Lung cancer is a serious health problem and leading cause of death worldwide due to its high incidence mortality. More than 80% lung cancers feature non-small cell histology. Over few decades, systemic chemotherapy surgery are the only treatment options in this type tumor but their limited efficacy overall poor survival patients, there an urge develop newer therapeutic strategies which circumvent problems. Enhanced knowledge translational science molecular biology have revealed that tumors carry diverse driver gene mutations adopt different intracellular pathways carcinogenesis. Hence, development targeted agents against subgroups harboring critical attractive approach for treatment. Targeted therapies clearly more preferred nowadays over because they target specific molecules resulting with enhanced activity reduced toxicity normal tissues. Thus, review encompasses comprehensive updates on (NSCLC) potential challenges acquired drug resistance faced field therapy along imminent modalities cancer.